Eli Lilly and Co at Cowen Health Care Conference (Virtual) Transcript
Good morning. I'd like to welcome Eli Lilly to Cowen's 42nd Annual Healthcare Conference. We're very, very pleased to have Lilly back with us again this year. Let me say that Cowen is recommending Eli Lilly stock because we see above-average growth driven by differentiated new products, which has been a feature of Lilly for virtually 10 years, if not more. So exciting situation that we think investors should be participating in.
So representing the company is Anat Ashkenazi, who is the CFO of the company. So Anat, thank you so much for being with us today.
Questions & Answers
I'd like to start out with one of the most exciting developments that will occur in 2022, and that is tirzepatide. And I'm curious, is Lilly ready to launch immediately post-approval? Or will it depend on what the label says and some time will be needed to train the sales
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
